Portal de Periódicos da CAPES

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome

2018; Elsevier BV; Volume: 4; Issue: 3 Linguagem: Inglês

10.1016/j.ekir.2018.11.010

2468-0249

Andrew M. Siedlecki, Nicole M. Isbel, Johan Vande Walle, Jennifer James Eggleston, David J. Cohen, Christoph Licht, Véronique Frémeaux‐Bacchi, Gema Ariceta, Gianluigi Ardissino, Fádi Fakhouri, Larry A. Greenbaum, Sally Johnson, Franz Schaefer, Marie Ann Scully, Leonard Woodward, Masayo Ogawa, Christoph Gasteyger, Miquel Blasco, Donata Cresseri, Galina Generolova, Nicholas J.A. Webb, Patricia Hirt‐Minkowski, Natal'ya L'vovna Kozlovskaya, Danny Landau, Anne‐Laure Lapeyraque, Chantal Loirat, Christoph J. Mache, Michal Malina, Leena Martola, Annick Massart, Éric Rondeau, Lisa Sartz,

Renal Diseases and Glomerulopathies

Recurrence of atypical hemolytic uremic syndrome (aHUS) in renal allografts is common, leading to dialysis and graft failure. Pretransplant versus posttransplant initiation of eculizumab treatment in patients with aHUS has not been rigorously investigated. We hypothesized eculizumab pretransplant would reduce dialysis incidence posttransplant.Of patients enrolled in the Global aHUS Registry (n = 1549), 344 had ≥1 kidney transplant. Of these, 188 had received eculizumab. Eighty-eight patients (47%) were diagnosed with aHUS and received eculizumab before, and during, their most recent transplant (group 1). A total of 100 patients (53%; group 2) initiated eculizumab posttransplantation. This second group was subdivided into those diagnosed with aHUS before (n = 52; group 2a) or after (n = 48; group 2b) their most recent transplant.Within 5 years of transplantation, 47 patients required dialysis; the risk of dialysis after transplantation was significantly increased in group 2b (hazard ratio [HR] 4.6; confidence interval [CI] 1.7-12.4) but not 2a (HR 2.3; CI 0.9-6.2). Graft function within 6 months of transplantation was significantly better in group 1 (median estimated glomerular filtration rate of 60.6 ml/min per 1.73 m2) compared with 31.5 and 9.6 ml/min per 1.73 m2 in groups 2a (P = 0.004) and 2b (P = 0.0001), respectively. One meningococcal infection (resolved with treatment) and 3 deaths (deemed unrelated to eculizumab) were reported.Outcomes for transplant patients with aHUS treated with eculizumab were improved compared with previous reports of patients with aHUS not treated with eculizumab. Our findings suggest delayed aHUS diagnosis and therefore treatment is associated with an increased risk of dialysis posttransplantation and reduced allograft function.